Gangliocytoma masquerading as a prolactinoma. Case report.
The authors describe the case of a 36-year-old man who presented with bitemporal hemianopsia and a serum prolactin concentration of 1440 ng/ml. Magnetic resonance imaging of the pituitary revealed a presumed macroadenoma with suprasellar and temporal lobe extension. Although the patient's prolactin level was lowered to 55 ng/ml by bromocriptine therapy, no tumor shrinkage occurred. Fourteen months later, progression of visual field defects necessitated transsphenoidal resection, which was incomplete. Immunocytochemical analysis of the biopsy tissue was positive for prolactin and, in view of the clinical picture, more detailed analysis was not performed. External-beam radiotherapy was given 2 years later because of enlargement of residual tumor. Subsequently, despite a fall in the serum prolactin concentration to less than 20 ng/ml in response to the course of bromocriptine, the mass displayed further extension into the temporal lobe. Nine years after the patient's initial presentation, he underwent transfrontal craniotomy for sudden deterioration in visual acuity caused by hemorrhage into the mass. No adenohypophyseal tissue was identified in the resected tissue. The mass was composed of dysplastic neurons that were strongly immunoreactive for synaptophysin and neurofilament (indicating neural differentiation) and prolactin. Review of the original biopsy specimen indicated that the prolactin-positive cells had striking neuronal morphological characteristics. The final diagnosis in this case is prolactin-secreting gangliocytoma. Although exceedingly rare, this disease must be added to the differential diagnosis in cases of "prolactinoma" when bromocriptine therapy is followed by a marked decline in serum prolactin that is not accompanied by significant tumor shrinkage. Furthermore, in such instances, consideration should be given to "obtaining a biopsy sample prior to electing for radiotherapy.
McCowen
K C
KC
Harvard Vanguard Medical Associates, Boston, Massachusetts, USA. karen.mccowen@joslin.harvard.edu
Glickman
J N
JN
Black
P M
PM
Zervas
N T
NT
Lidov
H G
HG
Garber
J R
JR
D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005500:Follow-Up Studies; D005729:Ganglioneuroma / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D018365:Neoplasm, Residual / Q000532:radiotherapy; D016900:Neurofilament Proteins / Q000032:analysis; D010911:Pituitary Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D011388:Prolactin / Q000032:analysis; D015175:Prolactinoma / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D016708:Synaptophysin / Q000032:analysis; D013702:Temporal Lobe / Q000473:pathology
D006727:Hormone Antagonists; D016900:Neurofilament Proteins; D016708:Synaptophysin; D001971:Bromocriptine; D011388:Prolactin